**GlaxoSmithKline (GSK)** is a leading global biopharma company headquartered in Brentford, UK, uniting science, technology, and talent to develop vaccines, specialty medicines, and consumer healthcare products aimed at preventing and treating diseases like cancer, heart failure, migraines, hepatitis, and respiratory infections.[1][2][5] GSK's roots trace to 1715 with London’s Plough Court Pharmacy, founded by Silvanus Bevan, evolving into Allen & Hanburys; in the US, John K. Smith opened a Philadelphia drugstore in 1830, becoming Smith Kline & Co. by 1875.[1][2][6] Key expansions included Glaxo Laboratories' 1935 incorporation, acquisitions like Allen & Hanburys (1958) and Allergan (1982), and SmithKline's mergers with Beckman (1982) and Beecham (1989).[1][3][4] The modern GSK formed in 2000 via Glaxo Wellcome's merger with SmithKline Beecham, creating a pharmaceutical powerhouse with R&D hubs in the US, UK, Belgium, and China.[2][3][4] **Achievements** spotlight innovations like the first malaria vaccine RTS,S (2014), essential medicines (amoxicillin, zidovudine), antivirals (Valtrex succeeding Zovirax), and blockbusters for herpes, whooping cough, and influenza.[1][2][4] GSK targets impacting 2.5 billion people by 2030 through cellular mapping, digital twins, and organoids in drug discovery.[5] Today, under CEO Emma Walmsley, GSK reports $32.17 billion annual revenue and $3.5 earnings per share in the $1.5 trillion pharma sector, focusing on vaccines, HIV, oncology, and consumer brands amid strategic swaps like its